

Yale Liver Center Research Seminar

*Presented by Yale School of Medicine,
Department of Internal Medicine*

Genomics and Cancer Biomarkers for HCC: Potential Applications in Surveillance, Diagnosis, Patient Outcomes, and Personalized Therapy

Lewis Roberts, MB, ChB, PhD

Professor of Medicine

Division of Gastroenterology & Hepatology
Mayo Clinic

Tuesday, October 5, 2021 | 5:00-6:00PM

<https://zoom.us/j/98883456668?pwd=RUYwdVBkbndjTW1RUHlmYlNYU292QT09&from=addon>

Host: Mario Strazzabosco, MD, PhD

Course Directors: Yasuko Iwakiri, PhD and Joseph Lim, MD

To record your attendance to this activity, text the Activity Code (29416) to 203-442-9435.

There is no corporate support for this activity. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** Need for improved surveillance and early detection of liver cancer to improve patient outcomes. Need for better diagnostic methods to confirm the diagnosis of liver cancer in indeterminate cases. Need for better ways to assess outcomes of patients with liver and biliary tract cancers in order to improve patient selection for clinical trials and prognostic information for patients and their providers. Need for improvements in effective personalized precision treatments for patients with hepatobiliary cancers. **Objectives:** 1. Participants will be able to describe the relationship between surveillance, early detection of liver cancer, and improved patient outcomes 2. Participants will be able to describe the need for improved methods of diagnosis of liver cancer in those at risk for liver cancer 3. Participants will be able to explain how the basis for differences in response to different therapies may be rooted in differences in tumor genomics and biomarkers levels. **Faculty Disclosures:** M Strazzabosco – Engitix. L Roberts - Honoraria-AstraZeneca | Eisai, Inc. | Honoraria-Genentech, Inc. | Honoraria-Roche | Grant and Advisory Board-Gilead | Grant funding and Advisory Board-Bayer Corporation | Grant Funding-Ariad Pharmaceuticals | Grant Funding-BTG International | Advisory Board, Grant Funding-Exact Sciences | Grant Funding-Glycotest, Inc | Advisory Board-QED Therapeutics, Inc | Grant Funding-RedHill | Grant Funding-TARGET PharmaSolutions | Advisory Board-TAVEC | Grant Funding-Wako Diagnostics | Honoraria-The Lynx Group, LLC | Honoraria-MJH Life Sciences | Honoraria-CCO-Clinical Care Options | Honoraria-MedEd Design webinar | Honoraria-Global Life Sciences | Honoraria-Pontifax - | Grant Funding-Fujifilm Medical Systems . It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**